Table S3.

Effect of ACEi monotherapy or triple therapy (AAA) with a combination of an ACEi (captopril) plus a type I (AT1) (valsartan) and a type 2 (AT2) Ang II receptor blocker (PD122139) on cardiac structure and function after I/R in WT mice

MeasurementsI/R + vehicleI/R + ACEiI/R + AAAP value (ACEi vs. AAA)
LV ED diameter, mm4.74 ± 0.14.18 ± 0.1**4.45 ± 0.170.29
LV ES diameter, mm4.13 ± 0.133.5 ± 0.13**3.69 ± 0.190.63
LV FW thickness at diastole, mm0.63 ± 0.020.65 ± 0.020.66 ± 0.040.97
LV FW thickness at systole, mm0.83 ± 0.030.88 ± 0.020.88 ± 0.051.00
LV ED volume, µL106 ± 5.679.2 ± 4.3**92.5 ± 8.10.27
LV ES volume, µL77.5 ± 5.753.2 ± 4.1**61 ± 7.80.62
Ejection fraction, %28.3 ± 1.7534.8 ± 2*36.6 ± 2.6*0.56
n212221
  • ED, end-diastolic; ES, end-systolic; FW, free wall; LV, left ventricle. Data are represented as mean ± SEM. Values were compared by using one-way ANOVA. Tukey’s post hoc test was used for multiple comparisons and each P value adjusted to account for multiple comparisons. For comparisons with the vehicle group: *P < 0.05; **P < 0.01. P values for comparisons between ACEi and AAA groups are indicated.